Druggability evaluation highlighted four protein biomarkers, ITGB2, GP1BA, ACADSB and COX6B1, which are already targeted for dry eye disease, inflammation, seizure and bile acid synthesis disorder, respectively. This evidence concerns the gene COX6B1 and Disorder of bile acid synthesis.